sofosbuvircontaining

Sofosbuvir-containing refers to pharmaceutical products or regimens that include the antiviral sofosbuvir, a nucleotide analogue inhibitor of the hepatitis C virus (HCV) RNA polymerase NS5B. Sofosbuvir is a prodrug that is converted inside cells to the active triphosphate, which inhibits viral RNA synthesis and acts as a chain terminator. In clinical use, sofosbuvir is combined with other agents as part of direct-acting antiviral (DAA) regimens, offering broad activity across multiple HCV genotypes.

Common sofosbuvir-containing regimens include fixed-dose combinations such as sofosbuvir/ledipasvir (Harvoni), sofosbuvir/velpatasvir (Epclusa), and sofosbuvir/velpatasvir/voxilaprevir (Vosevi). These regimens are designed to achieve sustained virologic response (SVR), which is considered a cure in the majority of treated patients, with regimens tailored to genotype, treatment history, and liver disease severity. Treatment durations typically range from 8 to 12 weeks, though longer durations or specific combinations may be used in certain circumstances.

Pharmacology and safety considerations include the renal and hepatic handling of the drug and potential drug–drug interactions. Sofosbuvir is renally excreted, and kidney function can influence its use in some regimens. Interactions with strong inducers or inhibitors of transporter pathways can affect sofosbuvir exposure and regimen effectiveness. Common adverse effects are generally mild and include fatigue and headache, with more serious events being uncommon. Sofosbuvir-containing regimens have transformed hepatitis C care by enabling highly effective, well-tolerated, once-daily oral therapy in many patients. Availability and recommendations vary by country and patient characteristics, including liver function and prior treatment history.